AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihyperglycaemics	1314	10238-21-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: glyburide glibenclamide glicuformine	An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide. Molecular weight: 494 Formula: C23H28ClN3O5S CLOGP: 4.24 LIPINSKI: 0 HAC: 8 HDO: 3 TPSA: 113.60 ALOGS: -5.38 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

glyburide
glibenclamide
glicuformine

An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.

Molecular weight: 494
Formula: C23H28ClN3O5S
CLOGP: 4.24
LIPINSKI: 0
HAC: 8
HDO: 3
TPSA: 113.60
ALOGS: -5.38
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7	mg	O
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.08 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.82 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC	17
kinase-selectivity-class	AXL,BRAF,CDK9,EIF2AK3,GRK2,MAPK7,PDK4,SIK2,STK33,TTK	10
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
May 1, 1984	FDA	SANOFI AVENTIS US
May 24, 2018	EMA	Ammtek

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	817.03	12.13	386	23042	69462	90535557
Blood glucose increased	409.74	12.13	273	23155	94973	90510046
Cardiac failure congestive	182.20	12.13	172	23256	98522	90506497
Myocardial infarction	169.99	12.13	171	23257	105801	90499218
Coronary artery disease	153.15	12.13	100	23328	33523	90571496
Blood glucose decreased	148.37	12.13	86	23342	23343	90581676
Lactic acidosis	146.39	12.13	114	23314	50349	90554670
Diabetes mellitus inadequate control	127.46	12.13	72	23356	18612	90586407
Glycosylated haemoglobin increased	103.53	12.13	59	23369	15503	90589516
Off label use	89.74	12.13	92	23336	1102160	89502859
Hyperglycaemia	70.44	12.13	76	23352	50894	90554125
Hypoglycaemic coma	69.73	12.13	27	23401	2963	90602056
Mucosal erosion	66.63	12.13	23	23405	1822	90603197
Glossodynia	64.26	12.13	5	23423	321774	90283245
Contraindicated product administered	56.19	12.13	8	23420	320131	90284888
Product use in unapproved indication	55.42	12.13	10	23418	336226	90268793
Alopecia	53.23	12.13	31	23397	495040	90109979
Hyperkalaemia	51.13	12.13	73	23355	64891	90540128
Synovitis	47.91	12.13	13	23415	329739	90275280
Pericarditis	46.82	12.13	7	23421	270144	90334875
Renal failure	46.66	12.13	104	23324	130903	90474116
Acute kidney injury	45.92	12.13	184	23244	320203	90284816
Torsade de pointes	45.53	12.13	35	23393	15147	90589872
Lower respiratory tract infection	44.59	12.13	6	23422	250653	90354366
Wound	43.91	12.13	12	23416	302968	90302051
Maternal exposure during pregnancy	39.45	12.13	22	23406	360041	90244978
Diabetic ketoacidosis	38.37	12.13	39	23389	24368	90580651
Infusion related reaction	38.25	12.13	31	23397	416749	90188270
Ketoacidosis	36.64	12.13	21	23407	5574	90599445
Fibromyalgia	36.54	12.13	5	23423	206264	90398755
Blood glucose fluctuation	35.78	12.13	20	23408	5063	90599956
Blood glucose abnormal	35.50	12.13	25	23403	9467	90595552
Cerebrovascular accident	35.26	12.13	90	23338	123443	90481576
Psoriatic arthropathy	35.09	12.13	8	23420	228327	90376692
Transient ischaemic attack	34.68	12.13	49	23379	43127	90561892
Diabetes mellitus	34.58	12.13	61	23367	64814	90540205
Intentional product use issue	34.56	12.13	7	23421	216885	90388134
Irritable bowel syndrome	34.53	12.13	6	23422	207442	90397577
Genital erosion	34.38	12.13	10	23418	453	90604566
Pancreatitis	33.84	12.13	63	23365	69763	90535256
Hypoglycaemic encephalopathy	32.72	12.13	9	23419	332	90604687
Arthropathy	32.66	12.13	28	23400	366214	90238805
Toxic epidermal necrolysis	32.39	12.13	41	23387	32487	90572532
Blood urea increased	31.34	12.13	39	23389	30374	90574645
Liver injury	30.53	12.13	4	23424	170563	90434456
Metabolic acidosis	30.51	12.13	53	23375	55623	90549396
Blood pressure increased	30.44	12.13	116	23312	197101	90407918
Treatment failure	29.93	12.13	21	23407	303907	90301112
Bradyarrhythmia	29.92	12.13	14	23414	2447	90602572
Discomfort	29.70	12.13	17	23411	274318	90330701
Ischaemic cardiomyopathy	29.12	12.13	14	23414	2599	90602420
Hepatic steatosis	28.31	12.13	41	23387	36904	90568115
Rhabdomyolysis	27.06	12.13	48	23380	51208	90553811
Pancreatitis acute	26.61	12.13	37	23391	32078	90572941
Oedema peripheral	26.31	12.13	134	23294	257781	90347238
Fall	26.01	12.13	213	23215	481597	90123422
Dehydration	25.71	12.13	109	23319	194338	90410681
Drug interaction	25.71	12.13	140	23288	276313	90328706
Treatment noncompliance	25.48	12.13	47	23381	51680	90553339
Hyperhidrosis	25.14	12.13	85	23343	136220	90468799
Product use issue	25.07	12.13	29	23399	329890	90275129
Hypoglycaemic unconsciousness	25.02	12.13	9	23419	805	90604214
Drug ineffective	24.35	12.13	235	23193	1384063	89220956
Asthenia	24.16	12.13	227	23201	533524	90071495
Peripheral swelling	23.86	12.13	44	23384	413062	90191957
Bursitis	23.77	12.13	3	23425	131651	90473368
Carcinoid tumour of the stomach	23.54	12.13	6	23422	164	90604855
Impaired healing	23.29	12.13	16	23412	234183	90370836
Anaphylactic reaction	23.16	12.13	62	23366	87462	90517557
General physical health deterioration	23.12	12.13	35	23393	355080	90249939
Blood creatinine increased	23.08	12.13	68	23360	101318	90503701
Abdominal discomfort	21.70	12.13	58	23370	477270	90127749
Myocardial ischaemia	21.58	12.13	22	23406	13792	90591227
Wrong product administered	21.53	12.13	17	23411	7648	90597371
Hypersensitivity	20.85	12.13	55	23373	454622	90150397
Lymphocyte count increased	20.77	12.13	13	23415	4046	90600973
Muscle injury	20.51	12.13	10	23418	176644	90428375
Hepatic enzyme increased	20.32	12.13	39	23389	360697	90244322
Diabetic retinopathy	20.03	12.13	11	23417	2691	90602328
Atrial fibrillation	19.31	12.13	77	23351	133534	90471485
Autoimmune myositis	19.21	12.13	6	23422	347	90604672
Mobility decreased	19.08	12.13	22	23406	250712	90354307
Gastrointestinal disorder	19.03	12.13	23	23405	256664	90348355
Swelling	18.98	12.13	51	23377	419007	90186012
Stomatitis	18.93	12.13	26	23402	274672	90330347
Angina pectoris	18.56	12.13	35	23393	39125	90565894
Macular oedema	18.52	12.13	13	23415	4896	90600123
Pulmonary oedema	18.51	12.13	46	23382	62034	90542985
Enterochromaffin cell hyperplasia	18.36	12.13	4	23424	54	90604965
Alcoholism	18.13	12.13	9	23419	1791	90603228
Heart rate increased	17.89	12.13	67	23361	112835	90492184
Acute myocardial infarction	17.55	12.13	32	23396	34858	90570161
Weight decreased	17.38	12.13	162	23266	379748	90225271
Syncope	17.24	12.13	74	23354	132589	90472430
Hypophagia	16.88	12.13	32	23396	35905	90569114
Condition aggravated	16.83	12.13	88	23340	595457	90009562
Meralgia paraesthetica	16.63	12.13	6	23422	541	90604478
Acute coronary syndrome	16.49	12.13	17	23411	10796	90594223
Drug hypersensitivity	16.40	12.13	63	23365	463546	90141473
Strongyloidiasis	16.10	12.13	8	23420	1594	90603425
Sinusitis	16.10	12.13	41	23387	343047	90261972
Hepatic artery thrombosis	16.00	12.13	4	23424	101	90604918
Blood potassium increased	15.86	12.13	23	23405	20726	90584293
Loss of consciousness	15.81	12.13	75	23353	140163	90464856
Haematocrit decreased	15.77	12.13	34	23394	41798	90563221
Blood creatine phosphokinase increased	15.62	12.13	30	23398	33993	90571026
Gait disturbance	15.59	12.13	118	23310	260378	90344641
Lip discolouration	15.40	12.13	6	23422	669	90604350
Conjunctivitis	15.39	12.13	26	23402	26680	90578339
C-reactive protein abnormal	15.11	12.13	7	23421	127422	90477597
Oral mucosal discolouration	14.93	12.13	5	23423	361	90604658
Hyperventilation	14.89	12.13	13	23415	6715	90598304
Depressed level of consciousness	14.86	12.13	47	23381	72737	90532282
Factitious disorder	14.86	12.13	4	23424	136	90604883
Stevens-Johnson syndrome	14.85	12.13	27	23401	29349	90575670
Hypergastrinaemia	14.83	12.13	4	23424	137	90604882
Dizziness	14.81	12.13	224	23204	589060	90015959
Lung infiltration	14.80	12.13	19	23409	15263	90589756
Therapeutic product effect decreased	14.77	12.13	31	23397	277540	90327479
Diabetic neuropathy	14.72	12.13	11	23417	4563	90600456
Mouth ulceration	14.52	12.13	32	23396	39942	90565077
Joint swelling	14.42	12.13	74	23354	503226	90101793
Angina unstable	14.22	12.13	13	23415	7130	90597889
Atrioventricular block complete	14.20	12.13	15	23413	9796	90595223
Necrotising myositis	14.19	12.13	6	23422	825	90604194
Circulatory collapse	14.03	12.13	24	23404	24880	90580139
Joint range of motion decreased	13.84	12.13	9	23419	135634	90469385
Completed suicide	13.83	12.13	74	23354	144984	90460035
Tooth abscess	13.73	12.13	19	23409	16394	90588625
Therapeutic product effect incomplete	13.71	12.13	18	23410	193878	90411141
Cholelithiasis	13.69	12.13	37	23391	52469	90552550
Brain death	13.68	12.13	10	23418	4011	90601008
Product physical consistency issue	13.40	12.13	6	23422	948	90604071
Benzodiazepine drug level increased	13.39	12.13	4	23424	199	90604820
Arrhythmia	13.29	12.13	32	23396	42300	90562719
Cardiac arrest	13.22	12.13	58	23370	104877	90500142
Activated partial thromboplastin time prolonged	13.21	12.13	13	23415	7812	90597207
Blood triglycerides increased	13.15	12.13	17	23411	13744	90591275
Migraine	13.13	12.13	18	23410	190374	90414645
Cardiomegaly	13.06	12.13	20	23408	18905	90586114
Ventricular hypertrophy	12.84	12.13	9	23419	3382	90601637
Cardiac disorder	12.80	12.13	38	23390	56834	90548185
Peripheral venous disease	12.77	12.13	3	23425	83918	90521101
Interstitial lung disease	12.66	12.13	46	23382	76359	90528660
Dialysis	12.44	12.13	15	23413	11314	90593705
Gastric disorder	12.43	12.13	27	23401	33357	90571662
Sleep disorder	12.42	12.13	20	23408	198010	90407009
Hospitalisation	12.40	12.13	9	23419	128091	90476928
Renal cyst	12.38	12.13	16	23412	12934	90592085
Anaemia of malignant disease	12.25	12.13	5	23423	629	90604390
Coronary artery occlusion	12.24	12.13	13	23415	8541	90596478
Prescribed overdose	12.15	12.13	5	23423	97620	90507399

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	1252.26	13.02	652	26150	59202	42535331
Blood glucose increased	260.22	13.02	274	26528	73425	42521108
Blood glucose decreased	187.89	13.02	115	26687	14104	42580429
Myocardial infarction	171.04	13.02	291	26511	123718	42470815
Off label use	153.25	13.02	108	26694	638227	41956306
Cardiac failure congestive	146.90	13.02	222	26580	85380	42509153
Coronary artery disease	130.80	13.02	165	26637	53555	42540978
Lactic acidosis	102.27	13.02	134	26668	45127	42549406
Glycosylated haemoglobin increased	99.88	13.02	75	26727	12849	42581684
Blood mercury abnormal	98.90	13.02	25	26777	257	42594276
Arteriosclerosis coronary artery	95.08	13.02	85	26717	18592	42575941
Hyperglycaemia	78.66	13.02	119	26683	45740	42548793
Low density lipoprotein decreased	64.70	13.02	26	26776	1278	42593255
Blood pressure systolic increased	61.91	13.02	82	26720	27886	42566647
5-hydroxyindolacetic acid in urine increased	61.82	13.02	16	26786	182	42594351
Counterfeit product administered	60.05	13.02	17	26785	277	42594256
Drug ineffective	58.88	13.02	202	26600	629995	41964538
Hepatic neoplasm	51.77	13.02	26	26776	2165	42592368
Cerebrovascular accident	48.70	13.02	153	26649	97007	42497526
Product use in unapproved indication	45.56	13.02	30	26772	184426	42410107
Metabolic acidosis	44.75	13.02	100	26702	51758	42542775
Product contamination	43.10	13.02	18	26784	977	42593556
Expired product administered	40.99	13.02	28	26774	4135	42590398
Hypoglycaemic coma	40.92	13.02	24	26778	2720	42591813
Myocardial ischaemia	40.73	13.02	53	26749	17709	42576824
Drug abuse	39.03	13.02	9	26793	104762	42489771
Pyrexia	38.93	13.02	123	26679	393919	42200614
Cellulitis gangrenous	38.80	13.02	12	26790	269	42594264
Diabetes mellitus inadequate control	38.57	13.02	48	26754	15342	42579191
Mental status changes	38.36	13.02	83	26719	42032	42552501
Haematocrit decreased	37.93	13.02	74	26728	34834	42559699
Platelet count normal	34.92	13.02	7	26795	21	42594512
5-hydroxyindolacetic acid increased	34.34	13.02	9	26793	108	42594425
Febrile neutropenia	34.03	13.02	40	26762	185663	42408870
Hyperkalaemia	33.46	13.02	119	26683	80339	42514194
Neutropenia	33.39	13.02	46	26756	199385	42395148
Hypoglycaemic encephalopathy	33.15	13.02	11	26791	311	42594222
Antineutrophil cytoplasmic antibody positive	32.98	13.02	25	26777	4340	42590193
Ischaemic cardiomyopathy	31.84	13.02	29	26773	6493	42588040
Blood creatinine increased	31.60	13.02	145	26657	109858	42484675
COVID-19	31.22	13.02	17	26785	115931	42478602
Hyperoxaluria	31.01	13.02	9	26793	161	42594372
Neoplasm	30.71	13.02	28	26774	6277	42588256
Mycotic allergy	30.47	13.02	25	26777	4866	42589667
Mite allergy	29.79	13.02	25	26777	5021	42589512
Neurological symptom	29.71	13.02	34	26768	9957	42584576
Capillaritis	29.36	13.02	18	26784	2210	42592323
Dust allergy	28.59	13.02	25	26777	5307	42589226
Blood follicle stimulating hormone increased	28.56	13.02	9	26793	215	42594318
Pancreatitis	28.30	13.02	75	26727	43193	42551340
Total lung capacity abnormal	28.29	13.02	23	26779	4420	42590113
Emotional distress	27.91	13.02	42	26760	16051	42578482
Spirometry abnormal	27.33	13.02	24	26778	5122	42589411
Neuritis	27.17	13.02	26	26776	6194	42588339
Pulmonary vasculitis	27.01	13.02	26	26776	6240	42588293
Conjunctivitis allergic	26.37	13.02	25	26777	5886	42588647
Acute kidney injury	25.87	13.02	348	26454	366989	42227544
Congenital absence of bile ducts	25.49	13.02	4	26798	0	42594533
Chest pain	25.18	13.02	162	26640	139368	42455165
Oedema peripheral	24.56	13.02	158	26644	135918	42458615
Fibrous histiocytoma	24.47	13.02	9	26793	347	42594186
Arteriosclerosis	24.43	13.02	42	26760	17947	42576586
Scrotal oedema	24.16	13.02	15	26787	1884	42592649
Forced expiratory volume decreased	22.74	13.02	26	26776	7604	42586929
Injury	22.66	13.02	46	26756	22270	42572263
Treatment failure	22.11	13.02	6	26796	62618	42531915
Otitis externa	22.01	13.02	12	26790	1182	42593351
Eosinophilic granulomatosis with polyangiitis	21.74	13.02	27	26775	8611	42585922
Oliguria	21.68	13.02	28	26774	9285	42585248
Asthenia	21.40	13.02	270	26532	280523	42314010
Thrombocytopenia	21.21	13.02	56	26746	190223	42404310
Normochromic normocytic anaemia	20.78	13.02	27	26775	9004	42585529
Renal failure	20.16	13.02	157	26645	143569	42450964
Diabetic neuropathy	20.01	13.02	19	26783	4483	42590050
Drug intolerance	19.94	13.02	13	26789	80411	42514122
Weight decreased	19.89	13.02	209	26593	207739	42386794
Hospitalisation	19.85	13.02	11	26791	74319	42520214
Blood pH decreased	19.24	13.02	14	26788	2284	42592249
Diabetic nephropathy	19.01	13.02	14	26788	2327	42592206
Deafness neurosensory	18.96	13.02	17	26785	3729	42590804
Hirsutism	18.86	13.02	7	26795	277	42594256
Coma	18.76	13.02	75	26727	53479	42541054
Hepatic pain	18.75	13.02	12	26790	1588	42592945
Body temperature decreased	18.72	13.02	33	26769	14380	42580153
Angina pectoris	18.52	13.02	54	26748	32842	42561691
Renal injury	18.45	13.02	30	26772	12250	42582283
Cardiac disorder	18.34	13.02	70	26732	48862	42545671
Cytokine release syndrome	18.31	13.02	3	26799	44524	42550009
Dizziness	17.44	13.02	236	26566	249018	42345515
Nephrocalcinosis	17.43	13.02	9	26793	794	42593739
Peripheral vascular disorder	17.36	13.02	19	26783	5298	42589235
Product complaint	17.20	13.02	20	26782	5957	42588576
Loss of consciousness	17.12	13.02	108	26694	92246	42502287
Drug ineffective for unapproved indication	17.11	13.02	4	26798	46159	42548374
Middle ear disorder	17.04	13.02	3	26799	3	42594530
Dyspepsia	17.04	13.02	61	26741	41291	42553242
Cutaneous lupus erythematosus	16.99	13.02	9	26793	837	42593696
Pancreatitis acute	16.92	13.02	53	26749	33511	42561022
Pulmonary alveolar haemorrhage	16.81	13.02	32	26770	14784	42579749
Quadriparesis	16.75	13.02	13	26789	2337	42592196
Nasal neoplasm	16.38	13.02	5	26797	107	42594426
Paratracheal lymphadenopathy	16.21	13.02	5	26797	111	42594422
Cataract	16.06	13.02	49	26753	30555	42563978
Blood glucose fluctuation	16.04	13.02	17	26785	4570	42589963
Myelosuppression	16.04	13.02	3	26799	40458	42554075
Poor dental condition	16.01	13.02	6	26796	244	42594289
Blood glucose	15.51	13.02	3	26799	7	42594526
Renal tubular necrosis	15.38	13.02	35	26767	18319	42576214
Death	15.21	13.02	207	26595	470978	42123555
Tympanic membrane disorder	15.18	13.02	4	26798	49	42594484
Areflexia	15.14	13.02	15	26787	3728	42590805
Condition aggravated	15.10	13.02	99	26703	260655	42333878
Lacunar infarction	14.95	13.02	14	26788	3246	42591287
Hypophagia	14.94	13.02	44	26758	26912	42567621
Leukopenia	14.89	13.02	15	26787	74731	42519802
Intentional overdose	14.88	13.02	68	26734	51388	42543145
Haemolytic anaemia	14.77	13.02	27	26775	12100	42582433
Vasculitis	14.24	13.02	34	26768	18360	42576173
Nodule	14.13	13.02	27	26775	12507	42582026
Cardiovascular disorder	14.11	13.02	28	26774	13337	42581196
Fear	14.10	13.02	25	26777	10940	42583593
Blood potassium decreased	14.00	13.02	36	26766	20348	42574185
Haemodialysis	13.99	13.02	24	26778	10236	42584297
Blood lactic acid increased	13.97	13.02	21	26781	8018	42586515
Shock	13.78	13.02	45	26757	29076	42565457
Hyperlipidaemia	13.76	13.02	37	26765	21479	42573054
Bladder cancer	13.73	13.02	32	26770	17015	42577518
Intentional product use issue	13.65	13.02	15	26787	71818	42522715
Acquired haemophilia	13.56	13.02	10	26792	1665	42592868
Macrosomia	13.51	13.02	4	26798	77	42594456
Dehydration	13.31	13.02	142	26660	141625	42452908
Blood glucose abnormal	13.08	13.02	19	26783	7034	42587499

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	2017.03	12.02	948	40931	115156	110432264
Blood glucose increased	543.51	12.02	429	41450	132067	110415353
Myocardial infarction	330.46	12.02	385	41494	191698	110355722
Cardiac failure congestive	282.19	12.02	316	41563	150684	110396736
Lactic acidosis	260.58	12.02	242	41637	92569	110454851
Coronary artery disease	253.34	12.02	213	41666	71477	110475943
Blood glucose decreased	240.70	12.02	146	41733	29342	110518078
Off label use	211.23	12.02	157	41722	1500028	109047392
Glycosylated haemoglobin increased	177.62	12.02	111	41768	23508	110523912
Hyperglycaemia	143.52	12.02	169	41710	84921	110462499
Diabetes mellitus inadequate control	123.12	12.02	97	41782	29678	110517742
Blood mercury abnormal	111.51	12.02	25	41854	257	110547163
Arteriosclerosis coronary artery	106.38	12.02	83	41796	25035	110522385
Acute kidney injury	100.56	12.02	491	41388	634939	109912481
Hyperkalaemia	93.39	12.02	177	41702	135619	110411801
Hypoglycaemic coma	92.07	12.02	44	41835	5489	110541931
Cerebrovascular accident	90.34	12.02	207	41672	181077	110366343
Drug ineffective	88.58	12.02	289	41590	1520251	109027169
Product use in unapproved indication	87.72	12.02	30	41849	447347	110100073
Metabolic acidosis	82.62	12.02	141	41738	99603	110447817
Low density lipoprotein decreased	75.35	12.02	26	41853	1396	110546024
Renal failure	75.07	12.02	222	41657	226352	110321068
5-hydroxyindolacetic acid in urine increased	69.73	12.02	16	41863	184	110547236
Counterfeit product administered	69.60	12.02	17	41862	260	110547160
Synovitis	68.21	12.02	11	41868	274081	110273339
Hypoglycaemic encephalopathy	66.38	12.02	20	41859	693	110546727
Alopecia	65.59	12.02	28	41851	364725	110182695
Blood creatinine increased	65.20	12.02	184	41695	182705	110364715
Hepatic neoplasm	65.10	12.02	31	41848	3836	110543584
Blood pressure systolic increased	63.11	12.02	113	41766	82878	110464542
Pemphigus	62.38	12.02	5	41874	214565	110332855
Glossodynia	57.32	12.02	8	41871	221996	110325424
Myocardial ischaemia	57.01	12.02	60	41819	26624	110520796
Helicobacter infection	56.53	12.02	3	41876	181874	110365546
Haematocrit decreased	54.13	12.02	93	41786	66024	110481396
Treatment failure	53.60	12.02	19	41860	277215	110270205
Contraindicated product administered	53.43	12.02	14	41865	248253	110299167
Pericarditis	51.88	12.02	10	41869	219104	110328316
Lower respiratory tract infection	49.92	12.02	15	41864	243091	110304329
Mental status changes	47.17	12.02	95	41784	76027	110471393
Maternal exposure during pregnancy	46.71	12.02	19	41860	254864	110292556
Arthropathy	45.73	12.02	26	41853	287496	110259924
Mucosal erosion	45.60	12.02	22	41857	2802	110544618
Infusion related reaction	44.72	12.02	47	41832	381115	110166305
Irritable bowel syndrome	44.62	12.02	5	41874	164210	110383210
Cellulitis gangrenous	44.22	12.02	13	41866	413	110547007
Ketoacidosis	44.16	12.02	34	41845	10053	110537367
Peripheral swelling	43.93	12.02	53	41826	403981	110143439
Antineutrophil cytoplasmic antibody positive	43.65	12.02	26	41853	5050	110542370
Arteriosclerosis	43.08	12.02	50	41829	24717	110522703
Intentional product use issue	43.02	12.02	20	41859	247886	110299534
Drug hypersensitivity	42.89	12.02	66	41813	454024	110093396
Ischaemic cardiomyopathy	41.79	12.02	30	41849	7981	110539439
Transient ischaemic attack	41.03	12.02	81	41798	63901	110483519
Joint swelling	40.28	12.02	66	41813	442779	110104641
Fibromyalgia	40.04	12.02	8	41871	170901	110376519
Hyperhidrosis	39.57	12.02	158	41721	187140	110360280
Hepatic enzyme increased	39.43	12.02	38	41841	320854	110226566
Loss of consciousness	39.41	12.02	163	41716	196143	110351277
Wound	39.03	12.02	20	41859	234417	110313003
Neurological symptom	38.64	12.02	38	41841	15570	110531850
Gastrointestinal disorder	38.30	12.02	22	41857	241930	110305490
Blood glucose fluctuation	38.27	12.02	28	41851	7670	110539750
Platelet count normal	38.21	12.02	7	41872	22	110547398
Total lung capacity abnormal	38.18	12.02	23	41856	4560	110542860
Drug abuse	38.17	12.02	10	41869	177401	110370019
Mite allergy	37.99	12.02	25	41854	5778	110541642
Hypersensitivity	37.88	12.02	59	41820	403939	110143481
Pulmonary vasculitis	37.54	12.02	26	41853	6534	110540886
5-hydroxyindolacetic acid increased	37.52	12.02	9	41870	127	110547293
Mycotic allergy	37.41	12.02	25	41854	5929	110541491
Dust allergy	37.23	12.02	25	41854	5976	110541444
Product contamination	37.22	12.02	17	41862	1914	110545506
Psoriatic arthropathy	37.15	12.02	14	41865	196747	110350673
Blood urea increased	36.97	12.02	71	41808	54886	110492534
Spirometry abnormal	36.77	12.02	24	41855	5473	110541947
Capillaritis	36.38	12.02	18	41861	2421	110544999
Pancreatitis acute	35.90	12.02	74	41805	60200	110487220
Asthenia	35.58	12.02	408	41471	688591	109858829
Hypophagia	35.42	12.02	68	41811	52558	110494862
Pancreatitis	35.18	12.02	96	41783	93437	110453983
Torsade de pointes	34.99	12.02	43	41836	22557	110524863
Product use issue	34.82	12.02	40	41839	311655	110235765
Neuritis	34.73	12.02	26	41853	7373	110540047
Oedema peripheral	34.61	12.02	228	41651	328432	110218988
Normochromic normocytic anaemia	34.60	12.02	33	41846	13024	110534396
Dehydration	34.50	12.02	202	41677	279309	110268111
Expired product administered	34.16	12.02	27	41852	8293	110539127
Conjunctivitis allergic	33.98	12.02	25	41854	6906	110540514
Syncope	33.69	12.02	159	41720	202377	110345043
Rhabdomyolysis	33.41	12.02	111	41768	120290	110427130
Condition aggravated	33.35	12.02	154	41725	734682	109812738
Angina pectoris	33.08	12.02	73	41806	62222	110485198
Scrotal oedema	33.04	12.02	15	41864	1666	110545754
Renal injury	32.92	12.02	38	41841	18675	110528745
C-reactive protein abnormal	32.71	12.02	5	41874	129690	110417730
Pyrexia	32.60	12.02	203	41676	898062	109649358
Atrial fibrillation	32.36	12.02	172	41707	229470	110317950
Eosinophilic granulomatosis with polyangiitis	32.17	12.02	29	41850	10657	110536763
Bladder cancer	32.05	12.02	39	41840	20253	110527167
Mobility decreased	31.70	12.02	26	41853	237396	110310024
Acute myocardial infarction	31.52	12.02	86	41793	83691	110463729
Cardiac disorder	30.41	12.02	80	41799	76200	110471220
Blood pH decreased	30.29	12.02	20	41859	4649	110542771
Diabetic retinopathy	29.98	12.02	18	41861	3546	110543874
Angina unstable	29.97	12.02	34	41845	16398	110531022
Oliguria	29.70	12.02	36	41843	18621	110528799
Blood glucose abnormal	29.31	12.02	30	41849	12886	110534534
Discomfort	29.31	12.02	23	41856	214684	110332736
Emotional distress	29.02	12.02	57	41822	44790	110502630
Rash	29.02	12.02	187	41692	820777	109726643
Hyperoxaluria	28.53	12.02	9	41870	364	110547056
Impaired healing	28.23	12.02	20	41859	196697	110350723
Weight decreased	27.75	12.02	285	41594	467772	110079648
Blood follicle stimulating hormone increased	27.67	12.02	9	41870	402	110547018
Musculoskeletal stiffness	27.05	12.02	40	41839	279782	110267638
Poor dental condition	26.75	12.02	10	41869	677	110546743
Bursitis	26.69	12.02	8	41871	129910	110417510
Ill-defined disorder	26.67	12.02	13	41866	156840	110390580
Diabetic ketoacidosis	26.66	12.02	53	41826	42005	110505415
Shock	26.45	12.02	61	41818	53527	110493893
Haemodialysis	26.28	12.02	33	41846	17686	110529734
Febrile neutropenia	26.26	12.02	50	41829	316717	110230703
Night sweats	26.19	12.02	9	41870	133974	110413446
Neoplasm	25.61	12.02	26	41853	11061	110536359
Neutropenia	25.43	12.02	66	41813	374554	110172866
Headache	25.41	12.02	213	41666	882164	109665256
Peripheral vascular disorder	25.28	12.02	23	41856	8553	110538867
Blood pressure increased	25.25	12.02	176	41703	258197	110289223
Genital erosion	25.14	12.02	10	41869	801	110546619
Muscle injury	24.98	12.02	11	41868	140796	110406624
Fibrous histiocytoma	24.81	12.02	10	41869	829	110546591
Stomatitis	24.81	12.02	40	41839	270202	110277218
Liver injury	24.78	12.02	13	41866	150400	110397020
COVID-19	24.70	12.02	34	41845	245026	110302394
Chest pain	24.64	12.02	234	41645	376141	110171279
Abdominal discomfort	24.06	12.02	73	41806	393785	110153635
Swelling	23.71	12.02	62	41817	350979	110196441
Drug ineffective for unapproved indication	23.69	12.02	5	41874	102833	110444587
Fear	23.58	12.02	36	41843	23157	110524263
Macular oedema	23.16	12.02	20	41859	6946	110540474
Bladder transitional cell carcinoma	23.12	12.02	14	41865	2802	110544618
Myelosuppression	22.98	12.02	4	41875	94336	110453084
Ventricular hypertrophy	22.96	12.02	20	41859	7025	110540395
Coronary artery occlusion	22.80	12.02	29	41850	15743	110531677
Diabetic nephropathy	22.69	12.02	15	41864	3493	110543927
Cardiovascular disorder	22.68	12.02	35	41844	22725	110524695
Unresponsive to stimuli	22.53	12.02	64	41815	63726	110483694
Inflammation	22.45	12.02	24	41855	193214	110354206
General physical health deterioration	22.45	12.02	84	41795	425211	110122209
Forced expiratory volume decreased	21.91	12.02	26	41853	13150	110534270
Completed suicide	21.88	12.02	162	41717	242219	110305201
Body temperature decreased	21.58	12.02	45	41834	36890	110510530
Pulmonary alveolar haemorrhage	21.51	12.02	32	41847	20118	110527302
Migraine	21.45	12.02	20	41859	171632	110375788
Coma	21.42	12.02	95	41784	117774	110429646
Cardiomegaly	21.29	12.02	39	41840	29091	110518329
Diabetes mellitus	21.10	12.02	84	41795	99297	110448123
Hospitalisation	21.09	12.02	14	41865	142479	110404941
Diabetic neuropathy	21.08	12.02	19	41860	6980	110540440
Hepatic pain	20.95	12.02	16	41863	4674	110542746
Joint range of motion decreased	20.86	12.02	10	41869	121822	110425598
Lacunar infarction	20.80	12.02	18	41861	6268	110541152
Carcinoid tumour of the stomach	20.55	12.02	6	41873	186	110547234
Sciatica	20.27	12.02	5	41874	92394	110455026
Nephrocalcinosis	20.20	12.02	11	41868	1803	110545617
Wound infection	19.70	12.02	6	41873	96459	110450961
Depressed level of consciousness	19.29	12.02	89	41790	112189	110435231
Haemolytic anaemia	19.22	12.02	31	41848	20889	110526531
Blood creatine phosphokinase increased	19.06	12.02	66	41813	73011	110474409
Renal tubular necrosis	18.83	12.02	38	41841	30437	110516983
Anhedonia	18.66	12.02	26	41853	15402	110532018
Blindness	18.62	12.02	42	41837	36317	110511103
Haemoglobin decreased	18.49	12.02	159	41720	248568	110298852
C-reactive protein increased	18.40	12.02	34	41845	217885	110329535
Hypoglycaemic unconsciousness	18.19	12.02	9	41870	1211	110546209
Bradyarrhythmia	18.12	12.02	15	41864	4919	110542501
Lung infiltration	18.03	12.02	33	41846	24595	110522825
Rheumatoid arthritis	17.96	12.02	56	41823	299557	110247863
Blood glucose	17.59	12.02	4	41875	44	110547376
Drug intolerance	17.35	12.02	87	41792	406425	110140995
Hepatic steatosis	17.25	12.02	49	41830	48782	110498638
Liver function test increased	17.22	12.02	6	41873	88542	110458878
Intentional overdose	17.14	12.02	97	41782	132404	110415016
Hypotension	17.10	12.02	286	41593	523563	110023857
Cytokine release syndrome	17.08	12.02	3	41876	70303	110477117
Dry mouth	17.06	12.02	31	41848	199917	110347503
Cardiac arrest	16.91	12.02	130	41749	196623	110350797
Dilatation atrial	16.90	12.02	13	41866	3839	110543581
Live birth	16.81	12.02	3	41876	69481	110477939
Pemphigoid	16.49	12.02	28	41851	19679	110527741
Middle ear disorder	16.48	12.02	3	41876	9	110547411
Metabolic alkalosis	16.48	12.02	15	41864	5580	110541840
Toxicity to various agents	16.28	12.02	264	41615	480291	110067129
Brain death	16.26	12.02	16	41863	6557	110540863
Nasal neoplasm	16.15	12.02	5	41874	190	110547230
Insulin C-peptide increased	16.13	12.02	5	41874	191	110547229
Bundle branch block left	16.01	12.02	22	41857	12866	110534554
Otitis externa	15.97	12.02	11	41868	2741	110544679
Cataract	15.93	12.02	66	41813	79419	110468001
Drug interaction	15.92	12.02	272	41607	499911	110047509
Factitious disorder	15.90	12.02	5	41874	200	110547220
Areflexia	15.87	12.02	16	41863	6753	110540667
Peripheral venous disease	15.85	12.02	6	41873	84111	110463309
Therapeutic product effect decreased	15.85	12.02	44	41835	244272	110303148
Paratracheal lymphadenopathy	15.83	12.02	5	41874	203	110547217
Hyperlipidaemia	15.74	12.02	39	41840	35809	110511611
Arrhythmia	15.74	12.02	60	41819	69515	110477905
Renal cyst	15.45	12.02	26	41853	18146	110529274
Duodenal ulcer	15.38	12.02	27	41852	19487	110527933
Leukocytosis	15.26	12.02	50	41829	53778	110493642
Arthralgia	15.19	12.02	206	41673	779426	109767994
Enterochromaffin cell hyperplasia	15.19	12.02	4	41875	84	110547336
Infection	15.18	12.02	78	41801	362122	110185298
Alcoholism	15.15	12.02	12	41867	3695	110543725
Hirsutism	15.08	12.02	9	41870	1754	110545666
Respiratory symptom	14.91	12.02	23	41856	14922	110532498
Hyperlactacidaemia	14.87	12.02	17	41862	8269	110539151
Chronic obstructive pulmonary disease	14.84	12.02	81	41798	109077	110438343
Lower limb fracture	14.83	12.02	5	41874	75343	110472077
Hepatomegaly	14.81	12.02	28	41851	21386	110526034
Heart rate increased	14.65	12.02	99	41780	143735	110403685
Quadriparesis	14.61	12.02	13	41866	4694	110542726
Lethargy	14.50	12.02	72	41807	93504	110453916
Accidental exposure to product by child	14.48	12.02	11	41868	3187	110544233
Deafness neurosensory	14.40	12.02	18	41861	9601	110537819
International normalised ratio increased	14.33	12.02	68	41811	86704	110460716
Exposure during pregnancy	14.24	12.02	26	41853	167398	110380022
Blood potassium decreased	14.22	12.02	49	41830	54065	110493355
Respiratory failure	14.13	12.02	134	41745	215198	110332222
Sinusitis	14.13	12.02	61	41818	296627	110250793
Acquired haemophilia	14.06	12.02	10	41869	2621	110544799
Blood lactic acid increased	13.93	12.02	23	41856	15798	110531622
Tricuspid valve incompetence	13.85	12.02	29	41850	23844	110523576
Mitral valve disease	13.81	12.02	11	41868	3414	110544006
Blood triglycerides increased	13.80	12.02	29	41850	23897	110523523
Laryngeal pain	13.78	12.02	14	41865	5961	110541459
Meralgia paraesthetica	13.71	12.02	6	41873	611	110546809
Pancreatic carcinoma	13.61	12.02	22	41857	14850	110532570
Sleep disorder	13.46	12.02	35	41844	198609	110348811
Treatment noncompliance	13.39	12.02	59	41820	72931	110474489
Aspartate aminotransferase increased	13.36	12.02	105	41774	159831	110387589
Mitral valve incompetence	13.33	12.02	35	41844	33294	110514126
Halo vision	13.28	12.02	6	41873	659	110546761
Product complaint	13.24	12.02	21	41858	13951	110533469
Oral mucosal discolouration	12.92	12.02	5	41874	372	110547048
Nodule	12.78	12.02	34	41845	32597	110514823
Drug-induced liver injury	12.77	12.02	16	41863	120051	110427369
Lymphocyte count decreased	12.75	12.02	3	41876	57240	110490180
Vasculitis	12.68	12.02	36	41843	35837	110511583
Electrocardiogram T wave peaked	12.64	12.02	7	41872	1185	110546235
Drug resistance	12.47	12.02	3	41876	56371	110491049
Atrioventricular block complete	12.36	12.02	25	41854	20057	110527363
Blood bicarbonate decreased	12.32	12.02	13	41866	5784	110541636
Cholelithiasis	12.20	12.02	52	41827	63370	110484050
Acute coronary syndrome	12.17	12.02	27	41852	23085	110524335
Lip discolouration	12.16	12.02	6	41873	802	110546618
Coronary artery stenosis	12.12	12.02	20	41859	13738	110533682
Toxic epidermal necrolysis	12.08	12.02	48	41831	56679	110490741

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Insulin resistance	24.78	9.03	3	4	3	113943

Pharmacologic Action:

Source	Code	Description
ATC	A10BB01	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas
FDA CS	M0020795	Sulfonylurea Compounds
MeSH PA	D007004	Hypoglycemic Agents
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:38070	anti-arrhythmia drug
CHEBI has role	CHEBI:63726	neuroprotective agent
CHEBI has role	CHEBI:77194	EC 2.7.1.33 (pantothenate kinase) inhibitor
CHEBI has role	CHEBI:131770	EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
FDA EPC	N0000175608	Sulfonylurea

Related Drugs by ATC class:

A10BB Sulfonylureas 12 drugs

acetohexamide carbutamide chlorpropamide glibornuride gliclazide glimepiride glipizide gliquidone glisoxepide metahexamide tolazamide tolbutamide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Neonatal diabetes mellitus	indication	49817004	DOID:11717
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Acute vomiting	contraindication	23971007
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Dehydration	contraindication	34095006
Infectious disease	contraindication	40733004
Hepatic porphyria	contraindication	55056006	DOID:3133
Ketoacidosis	contraindication	56051008
Acute nephropathy	contraindication	58574008
Metabolic acidosis	contraindication	59455009
Hepatic failure	contraindication	59927004
Hemolytic anemia	contraindication	61261009	DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia	contraindication	62403005
Hypopituitarism	contraindication	74728003	DOID:9406
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Cobalamin deficiency	contraindication	190634004
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Sepsis syndrome	contraindication	238150007
Primary adrenocortical insufficiency	contraindication	373662000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Severe diarrhea	contraindication	409587002
Traumatic injury	contraindication	417746004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Severe Autonomic Insufficiency	contraindication
Severe Hypoxemia	contraindication
Radiography with IV Iodinated Contrast Agent	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.31	acidic
pKa2	12.71	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sulfonylurea receptor 1, Kir6.2	Ion channel	Q09428 Q14654	ABCC8_HUMAN KCJ11_HUMAN	BLOCKER	Kd	9.52	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN		IC50	5.28	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN	INHIBITOR	IC50	5.80	DRUG MATRIX
Peroxisome proliferator-activated receptor gamma	Nuclear hormone receptor	P37231	PPARG_HUMAN		Ki	6.18	CHEMBL
Cystic fibrosis transmembrane conductance regulator	Ion channel	P13569	CFTR_HUMAN	BLOCKER	Ki	4.66	IUPHAR
Sulfonylurea receptor 2, Kir6.2	Ion channel	O60706 Q14654	ABCC9_HUMAN KCJ11_HUMAN	BLOCKER	Ki	8.21	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	4.13	CHEMBL
NACHT, LRR and PYD domains-containing protein 3	Cytosolic other	Q96P20	NLRP3_HUMAN		IC50	4.92	CHEMBL
CDGSH iron-sulfur domain-containing protein 1	Membrane other	Q9NZ45	CISD1_HUMAN		Ki	5.78	CHEMBL
ATP-sensitive inward rectifier potassium channel 11	Ion channel		KCJ11_MOUSE	BLOCKER	IC50	5.70	IUPHAR
NACHT, LRR and PYD domains-containing protein 3	Cytosolic other		NLRP3_MOUSE		IC50	5	CHEMBL
Sur1-Trpm4; Sulfonylurea receptor 1 - Transient receptor potential melastatin 4	Ion channel		ABCC8_RAT TRPM4_RAT	INHIBITOR	EC50	7.32	SCIENTIFIC LITERATURE
Bile salt export pump	Transporter		ABCBB_RAT		IC50	5.55	CHEMBL

External reference:

ID	Source
4018078	VUID
N0000146417	NUI
D00336	KEGG_DRUG
4018078	VANDF
CHEBI:5441	CHEBI
GBM	PDB_CHEM_ID
CHEMBL472	ChEMBL_ID
2414	IUPHAR_LIGAND_ID
DB01016	DRUGBANK_ID
4815	RXNORM
4790	MMSL
597	MMSL
d00248	MMSL
000912	NDDF
384978002	SNOMEDCT_US
80870001	SNOMEDCT_US
C0017628	UMLSCUI
D005905	MESH_DESCRIPTOR_UI
3488	PUBCHEM_CID
2386	INN_ID
SX6K58TVWC	UNII
SX6K58TVWC	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8034	TABLET	1.50 mg	ORAL	ANDA	24 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8035	TABLET	3 mg	ORAL	ANDA	24 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8036	TABLET	6 mg	ORAL	ANDA	24 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8342	TABLET	1.25 mg	ORAL	ANDA	26 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8343	TABLET	2.50 mg	ORAL	ANDA	26 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8344	TABLET	5 mg	ORAL	ANDA	26 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-9364	TABLET	5 mg	ORAL	NDA AUTHORIZED GENERIC	25 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-9433	TABLET	2.50 mg	ORAL	NDA AUTHORIZED GENERIC	25 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-9477	TABLET	1.25 mg	ORAL	NDA AUTHORIZED GENERIC	25 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1742	TABLET	1.25 mg	ORAL	ANDA	22 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1743	TABLET	2.50 mg	ORAL	ANDA	22 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1744	TABLET	5 mg	ORAL	ANDA	22 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-232	TABLET	2.50 mg	ORAL	ANDA	21 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-300	TABLET	5 mg	ORAL	ANDA	21 sections
Glyburide-Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	10544-579	TABLET	5 mg	ORAL	ANDA	23 sections
Glyburide-Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	10544-580	TABLET	2.50 mg	ORAL	ANDA	23 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-467	TABLET	2.50 mg	ORAL	ANDA	22 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-468	TABLET	5 mg	ORAL	ANDA	22 sections
Glyburide and Metformin	HUMAN PRESCRIPTION DRUG LABEL	2	21695-568	TABLET, FILM COATED	5 mg	ORAL	ANDA	29 sections
GLYBURIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-056	TABLET	1.25 mg	ORAL	ANDA	11 sections
GLYBURIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-056	TABLET	1.25 mg	ORAL	ANDA	11 sections
GLYBURIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-057	TABLET	2.50 mg	ORAL	ANDA	11 sections
GLYBURIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-057	TABLET	2.50 mg	ORAL	ANDA	11 sections
GLYBURIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-058	TABLET	5 mg	ORAL	ANDA	11 sections
GLYBURIDE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-058	TABLET	5 mg	ORAL	ANDA	11 sections
glyburide-metformin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	23155-233	TABLET	1.25 mg	ORAL	ANDA	21 sections
glyburide-metformin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	23155-234	TABLET	2.50 mg	ORAL	ANDA	21 sections
glyburide-metformin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	23155-235	TABLET	5 mg	ORAL	ANDA	21 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	33261-209	TABLET	5 mg	ORAL	ANDA	22 sections
Glyburide	HUMAN PRESCRIPTION DRUG LABEL	1	33261-813	TABLET	2.50 mg	ORAL	ANDA	22 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

glibenclamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: